Form 4: OnKure Director Isaac Manke Acquires 5,258 Shares

OnKure Therapeutics Director Isaac Manke acquired 5,258 shares of Class A Common Stock through vested Restricted Stock Units, increasing his direct beneficial ownership to 20,583 shares.

Summary

• Isaac Manke, a Director at OnKure Therapeutics, Inc. (OKUR), acquired 5,258 shares of Class A Common Stock.
• The transaction occurred on December 31, 2025, and was filed on January 2, 2026.
• These securities are fully vested Restricted Stock Units (RSUs), with each RSU representing a contingent right to receive one share of Class A Common Stock.
• The RSUs were granted to Mr. Manke in lieu of a quarterly cash retainer, at his election, under the Issuer's Outside Director Compensation Policy.
• The acquisition price for these shares was $0.
• Following this transaction, Mr. Manke directly beneficially owns 20,583 shares of Class A Common Stock.
• The transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 7

Explanation: The acquisition of shares by a director, even through compensation, is generally viewed positively as it increases insider ownership and aligns management's interests with shareholders. The transaction being part of a 10b5-1 plan indicates a pre-planned, routine compensation event.

Positives

• A director, Isaac Manke, is increasing his direct beneficial ownership in OnKure Therapeutics, aligning his interests with those of shareholders.
• The acquisition of shares through RSUs demonstrates the company's use of equity-based compensation, which can incentivize long-term performance and commitment from its directors.

Future Outlook

This filing does not contain specific forward-looking statements or guidance regarding the company's future performance or strategic direction, focusing solely on an insider's equity transaction.

Industry Context

Insider transactions, such as the acquisition of shares by a director, are routinely monitored by investors as they can signal management's confidence in the company's future prospects. Equity compensation, like RSUs, is a standard practice across many industries to attract and retain talent and align management incentives with shareholder value creation.

Corporate Governance

Related Party Transactions

• Isaac Manke, a director, received 5,258 fully vested Restricted Stock Units (RSUs) as compensation, which is a transaction between the company and a related party (director).

Stakeholder Impact

• Shareholders may view the increased direct ownership by a director as a positive signal, indicating confidence in the company's future and better alignment of interests.
• Directors are impacted by receiving equity compensation, which ties their personal financial interests more closely to the company's stock performance.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction where a director received shares as compensation. While it indicates alignment of interests, it does not present new fundamental information or significant strategic shifts that would warrant a change in investment recommendation. It is a standard compensation event rather than an open market purchase reflecting a new investment decision.

Keywords

OnKure Therapeutics, OKUR, Isaac Manke, Director, Insider Transaction, Form 4, Restricted Stock Units, RSU, Equity Compensation, Class A Common Stock, Rule 10b5-1(c)